New Jersey is currently home to 1653 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
NCT06057935
Recruiting
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
Register for Updates
Collaborative Specialty Care for Gulf War Illness
NCT04403295
Recruiting
Gulf War Veterans (GWVs) with Gulf War Illness (GWI) do not receive the care they should in the Veterans Affairs (VA). The investigators' data show 70% of GWVs with Gulf War Illness (GWI) do not receive treatment recommendations for their GWI and 78% are NOT very satisfied with their care. The quality of care GWVs receive must improve. VA and DoD have invested hundreds of millions of dollars to develop new treatments for GWVs, without effective delivery methods GWVs will not benefit. This study... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/25/2024
Locations: East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ, East Orange, New Jersey
Conditions: Gulf War Illness
Register for Updates
A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract
NCT05868265
Recruiting
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an effective and safe treatment for people who have urothelial carcinoma of the upper urinary tract. Study participants will be people who are not eligible to receive or have chosen not to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all participants will be planning on having standard surgery to remove their tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Urothelial Carcinoma
Register for Updates
Lymphatic System Stimulation in Heart Failure
NCT05834400
Recruiting
The goal of this pilot clinical trial is to obtain preliminary data on the effects of lymphatic exercise training in patients with heart failure. The main question\[s\] it aims to answer are: 1. Does performing lymphatic exercise decrease fluid overload symptoms (shortness of breath, lower legs swelling, fatigue), thoracic fluid content, and body fluid level? 2. Does performing lymphatic exercise improve sleep and quality of life (QOL)? Participants with heart failure will be randomly assigned... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/24/2024
Locations: Cooper University Health Care (Cooper), Camden, New Jersey
Conditions: Heart Failure
Register for Updates
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT05180799
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Morristown Medical Center/Atlantic Health System, Morristown, New Jersey
Conditions: NSCLC, Melanoma
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: MD Anderson Cancer Center at Cooper, Camden, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311
Recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Summit Health, Berkeley Heights, New Jersey
Conditions: Lung Cancer, NSCLC
Register for Updates
Reducing Urban Cervical Cancer Disparities
NCT06416150
Recruiting
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and supplemental telephone-based Health Coaching for women who miss their appointment.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
10/23/2024
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Conditions: Cervical Cancer, Papilloma Viral Infection
Register for Updates
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Rutgers Cancer Institute, New Brunswick, New Jersey
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates
Trial of Therapeutic Hypothermia in Patients With ARDS
NCT04545424
Recruiting
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/23/2024
Locations: Cooper Health System, Camden, New Jersey
Conditions: Respiratory Distress Syndrome, Adult
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Select Advanced Solid Tumors
Register for Updates
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT05888831
Recruiting
The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumors
Register for Updates